🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Giuseppe Banna Meet-URO Ugo De Giorgi Sara Elena Rebuzzi pas_rescigno Thanks so much for the invitation & pleasure to be part of the Meet-URO meeting! congratulations for dynamic real life research in mRCC, looking forward international collaborations Gustave Roussy GETUG

Just got this late birthday gift ❤️ and happy july 14th!

Do differences matter in adjuvant #RCC IO-trials? Known variables: 👉 6 vs. 12 mo. of treatment 👉 M0 vs. M1/NED + M0 👉 #Pembro vs. #Nivo±Ipi vs. #Atezo Big unknowns are: 👉 role of pT2 vs. pT3 vs. N1 👉 sensitive subgroups (such as sarcomatoid, PD-L1+)

📢Our comprehensive review on circulating inflammatory cells in patients with metastatic breast cancer out now in Frontiers - Oncology. Thanks to Caterina Gianni and all other authors for the hard work and Ugo De Giorgi for inviting me to collaborate frontiersin.org/articles/10.33…

⚠️📢 Just published our last research. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First‐Line Combination Therapies Javier Molina Cerrillo Ugo De Giorgi veronica mollica Enrique Grande Camillo Porta

One week to #ESMO22 in Paris! Several important studies to be presented. Here’s our selection of the key GU presentations.

pharmastar.it/sharepage.html…

Really proud of the epub on Eur Urol of the results of the Italian MeetURO12 #trial coordinated by Francesca Vignani and Massimo Di Maio. No effect of maintainance PARP inhibitors after plt/gem in #bladdercancer #research #oncology sciencedirect.com/science/articl…

The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > bit.ly/3R2EokE Stephen Freedland, MD Pfizer Inc. Astellas Pharma US Ugo De Giorgi Martin Gleave BMJ_Open

I'm seeing some conflation of terminology around HRR-related gene mutations and the HRD phenotype in prostate cancer. Here's a slide I use to clarify. It matters because several HRR-related gene alterations (e.g. within ATM) do not appear to result in an HRD mutational signature.

Sharing thoughts about #biomarkers in early #breastcancer Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer mdpi.com/2026082 #mdpicancers via Cancers MDPI Ugo De Giorgi Marianna Sirico

Happy to share our work: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance Clinical Cancer Research aacrjournals.org/clincancerres/… Follow our tweetorial about this clinically important data 1/12

In a month’s time, we’ve learned that CD8 T cells aren’t the only effectors of immunotherapy response: stealing the show: eosinophils Cancer Cell and γδ T cells nature out today! The Netherlands Cancer Institute MarleenKokLab Karin de Visser de Miranda Lab rdcu.be/c3fd5 doi.org/10.1016/j.ccel…

AddThis | Home authors.elsevier.com/c/1gbOg5EIIgLp…

Ready for ASCO #GU23! Here's Meet-URO selection of the hot topics and key presentation. Looking forward to exciting data presented in San Francisco. Congrats to the Meet-URO group for the selected works!

Proud to be part of the team of this #practicechanging #EMBARK trial with neal shore Stephen Freedland, MD showing improved #MFS and trends for better survival for #enzalutamide with or without #ADT in #prostatecancer Alicia Morgans, MD, MPH presented @ #AUA23 Pfizer Inc. Astellas Pharma

Absolutely agree, Enrique. What a home run after the sobering start of IPI-NIVO in CM901. Current data: 👉CIS-GEM ➡️AVE✔️ 👉Platib-GEM + NIVO✔️ 👉EV + PEM❓ What will be your 1st line choice?

Just in Nature Medicine👉Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC #prostatecancer👉enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets⬇️open access👉tinyurl.com/wntrx75a OncoAlert PCF Science

Study conducted in 🇮🇹 and analyzed by our group in 🇪🇸. Led by Ugo De Giorgi! Thanks to him and to @prat_aleix for giving us carte blanche on this and more correlative biomarker analyses! Stay tuned ☝🏻 Universitat de Barcelona IDIBAPS Hospital Clínic Fara Brasó Maristany

Small but significative experience confirming the higher prognostic accuracy of the Meet-URO score also in mRCC patients receiving IO-TKI. Meet-URO Thank you to the Chinese Colleagues!! 😊 Waiting for the prospective Meet-URO 33 study!! 😀 doi.org/10.21203/rs.3.…